Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accumulated Expenses (2018 - 2024)

Zevra Therapeutics (ZVRA) has disclosed Accumulated Expenses for 8 consecutive years, with $6.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Expenses fell 42.59% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Dec 2024, down 42.59%, and an annual FY2024 reading of $6.1 million, down 42.59% over the prior year.
  • Accumulated Expenses was $6.1 million for Q4 2024 at Zevra Therapeutics, down from $10.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.7 million in Q4 2023 and bottomed at $53000.0 in Q4 2020.
  • Average Accumulated Expenses over 5 years is $3.9 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses tumbled 92.43% in 2020, then skyrocketed 1888.68% in 2021.
  • Year by year, Accumulated Expenses stood at $53000.0 in 2020, then surged by 1888.68% to $1.1 million in 2021, then soared by 58.73% to $1.7 million in 2022, then skyrocketed by 537.84% to $10.7 million in 2023, then tumbled by 42.59% to $6.1 million in 2024.
  • Business Quant data shows Accumulated Expenses for ZVRA at $6.1 million in Q4 2024, $10.7 million in Q4 2023, and $1.7 million in Q4 2022.